BioLargo, Inc.: Proactive Investors Interview: BioLargo retires $650,000 in debt, following its plan to focus more on equity-based transactions

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact.

Thursday, 4 March 2021

Proactive Investors Interview: BioLargo retires $650,000 in debt, following its plan to focus more on equity-based transactions

Source: Proactive Investors

BioLargo Inc (OTCQB:BLGO) CEO Dennis Calvert tells Proactive it has paid off $650,000 in debt, the bulk of which was scheduled to mature in August 2021. Calvert says aside from the debt carried by its partially owned subsidiary Clyra Medical, only SBA loans and fixed-price convertible debt remain on BioLargo's balance sheet, which falls in line with the company's goals to aggressively reduce or eliminate its convertible debt instruments in favor of equity-based transactions.

Thursday, 4 March 2021

Proactive Investors Interview: BioLargo retires $650,000 in debt, following its plan to focus more on equity-based transactions

No comments:

Post a Comment